11th & 12th February 2026
Royal Lancaster Hotel
Lancaster Terrace, London
CGTI convenes the leaders turning advanced therapies into commercial reality.
Cell and gene therapies that reach patients, not just papers.
The science has arrived. The manufacturing has not kept pace. Between breakthrough and batch release lies a gap that slides cannot close — only operational leaders can.
CGTI places advanced therapy leaders alongside the officers building tomorrow's manufacturing infrastructure.
Heads of CGT Manufacturing. CMC. Process Development. Technical Operations. Quality.
The decisions that govern manufacturability, scale-up and release.
Advanced therapies are rewriting medicine. But approval is not access.
Autologous complexity. Allogeneic scale. Viral vector capacity. Analytical methods that regulators will accept. Supply chains that patients can rely on.
The gap between clinical proof and commercial supply is where therapies stall or succeed.
CGTI exists because manufacturability cannot be an afterthought.
It must be designed in from the first experiment.
Senior leaders responsible for how advanced therapies are made, scaled and released:
-
Heads of Cell and Gene Therapy Manufacturing
-
CMC and Process Development Directors
-
VP Technical Operations and MSAT
-
Quality and Analytical Leaders
-
Supply Chain and External Manufacturing Officers
Decision-makers building production.
The people who turn approved therapies into treated patients.
Can we pay for it? Reimbursement, pricing and the economics that determine whether approved therapies reach patients.
Manufacturing
Can we make it more than once? Process robustness, yield and reproducibility at clinical and commercial scale.
Can we house it? Facilities, equipment and systems designed for the complexity genetic medicines demand.
Can we get it there? Vein-to-vein logistics, chain of custody and the final mile that matters most.
PAST SPEAKERS
Paolo Martini
Chief Research & Development Officer at ReAlta Life Sciences former CSO at Moderna
Warner Biddle
CEO at Kyverna Therapeutics former interim CEO at Kite a Gilead Company
Gwendolyn Binder PhD
President, Science and Technology at Cabaletta Bio
Who its curated for
Audience
Chief Operating Officers - transformation, scale, operating model
Heads of Manufacturing, MSAT and CMC process design, tech transfer, validation
Leaders in Data, AI and Automation - digital twins, advanced analytics, manufacturing IT
Quality and Regulatory Executives - QA, QMS, GxP, regulatory strategy
Also Welcome
Chief Data and Technology Officer
Head of Manufacturing IT/OT VP Supply Chain and Logistics Head of Cold Chain and Distribution
VP Quality Assurance
VP Regulatory Affairs
Head of Compliance and Release
CDMO executives: EVP Operations
Head of Client Programs
Why it matters
Science moves faster than the systems built to sustain it.
Applied intelligence turns information into infrastructure and links algorithms to execution - AI, automation and digital twins as living systems that learn and improve.
For biopharma it enables real-time oversight, continuous validation and reliability across networks.
For CGT it bridges innovation and access at scale without losing purpose.
CGTI 2026 | AIO
The Four Pillars of Advanced Therapy Intelligence
1. Intelligence
From data to design.
From design to delivery.
Where AI, automation and process analytics drive precision across CMC, development and manufacturing.
Why it matters: In a time of disruption and transformation, intelligence is human advantage - enabling leaders to anticipate, adapt and evolve beyond uncertainty.
2. Integration
From silos to synergy.
Bridging science, systems and supply through connected digital frameworks that learn, adapt and scale.
Why it matters: As global dynamics shift - tariffs, job cuts, supply constraints - integration becomes survival. True progress depends on unified systems that strengthen collaboration, resilience and trust.
3. Infrastructure
Where quality, innovation and agility align.
A living operational backbone powered by digital twins, modular design and compliant automation - engineered for flexibility and scale.
Why it matters: Resilient infrastructure is more than machinery. It’s the mindset that transforms volatility into opportunity and complexity into control.
4. Impact
From precision to purpose.
Where advanced therapies reach patients faster and sustain progress through adaptability, intelligence and shared responsibility.
Why it matters: In a world defined by change, impact is measured not just in outcomes - but in evolution. The ability to respond, rebuild and reimagine defines the future of healthcare.
ADVISORY & KEYNOTES
For the patients, we must do better.
Building pathways from research to patient access
ADVISORY
“Our very survival depends on our ability to stay awake, to adjust to new ideas, to remain vigilant and to face the challenge of change.” – Martin Luther King ...
Exploring automation and digital transformation in manufacturing
CGTI LONDON 2026
SUMMIT INSIGHTS
200+
Up to 200 decision-makers in person. Previous attendee demographics include 50% EMEA, 30% America and 20% ROW
20%
20% best-of-breed vendors providing solutions to combat the manufacturing, scale-up & R&D hurdles of today's C>
06
Journey of CXO presentations. Six insightful, powerful and inspirational talks from CXOs in the industry
02
Exclusive in-person networking, over 2 days in Barcelona, on the 10th and 11th of September
7+
Pre-scheduled and pre-qualified one-to-one meetings with delegates who influence or make a decision
90%
Over 90% of our attendance provided positive feedback. Please click here to see what our delegation has to say
WHY ATTEND
Exploring opportunities for small-scale CDMOs
Insights into key pain points such as shortage of talent and rising costs of supply chain
A deep dive into emerging biopharma pipelines and innovative emerging technologies
New innovations and strategies driving costs down and improving the manufacturing process
The promises and challenges of new therapeutic modalities
Leveraging innovation to bridge the gap from Gene to GMP
Executive training for commercial innovation and how to make a profitable growth
Navigating pricing, market access and reimbursement framework
Regulatory updates and compliance
As the industry scales to meet global demand, leaders face mounting geopolitical pressures, supply chain volatility and regulatory complexity - all while driving scientific innovation and ensuring patient access.
This summit offers exclusive access to insights, strategies and connections that can’t be found anywhere else. It’s not just another conference - it’s where executives shape the future of cell and gene therapy.
ACTION
-
Scale CGT from portfolio to patient access
-
MSAT playbook for scale and comparability
-
Connected supply and site readiness
-
Digital and data for QA and RTRT
-
Evidence and access that work
-
AI from design to factory (CGTI × DDIF)
-
Data that travels (CGTI × DDIF)
OUTCOME
-
MSAT access and supply aligned for speed
-
Faster tech transfer right first time release
-
Chain of identity protected faster turnaround
-
Real time oversight right first time release
-
Improved literacy donor services measurable outcomes
-
Models to RTRT right first time batches
-
FAIR standards and lineage traceable decisions
IMPACT
-
Cycle time reduced
-
Faster tech transfer
-
Fewer chain errors
-
Fewer deviations faster release
-
Higher participation better outcomes
-
Shorter cycle time
-
Faster tech transfer
SPEAKERS 2025
Be in the room where leaders decide
CGTI 2026 is where rare disease and cell and gene therapy leaders drive progress. An invite-only summit featuring selective partner showcases and strategic discussions.
